• Spatiotemporal regulation of protein kinases during thrombus formation remains elusive in vivo.
Introduction
Platelet aggregation at the sites of vascular injury is the primary event in thrombus formation [1] [2] [3] [4] . The dynamic features of platelet recruitment and aggregation leading to stable thrombus formation have been visualized by observing the microvasculature in the mouse mesentery and cremaster, which could be performed with conventional video widefield microscopy or confocal microscopy [5] [6] [7] [8] . Further studies using high-resolution imaging have revealed that platelet aggregation under high shear stress conditions can be divided into two phases [9] [10] [11] . Initially, the discoid platelets are tethered loosely to each other, and are often dislodged from the walls of blood vessels. In the later phase, the platelets change shape to form a core of fully activated platelets, overlaid with an unstable shell of less activated platelets.
In platelets during thrombus formation, collagen, von Willebrand factor (VWF) and soluble agonists such as thrombin, ADP and thromboxane A 2 (TxA 2 ) activate extracellular signal-regulated kinase (ERK) [12, 13] . ERK is required for ADP-induced TxA 2 generation and activation of integrin a IIb b 3 , which binds to fibronectin and fibrinogen, and thereby cross-links the activated platelets [14, 15] . In contrast to ERK, cAMP-dependent kinase (protein kinase A [PKA]) plays a major role in the inhibition of platelet activation [3, 13, [16] [17] [18] . Resting platelets are kept in a discoid and non-adherent state by endothelium-derived substances such as prostaglandin I 2 (PGI 2 ) and nitric oxide (NO). PGI 2 binding to the cognate G-protein-coupled receptor leads to adenylate cyclase-mediated elevation of intracellular cAMP, leading to PKA activation [17] . NO primarily activates cGMP-dependent kinase, but can also activate PKA via suppression of phosphodiesterase [19] .
Even with the recent advent of in vivo imaging, the spatiotemporal regulation of intracellular signaling molecules in vivo is only poorly understood. This issue is particularly important for the understanding of thrombosis, which is controlled by a complex interplay between inhibitory and activatory networks [13] . Therefore, biosensors based on the principle of F€ orster resonance energy transfer (FRET) have been developed to visualize the activities of protein kinases, small GTPases, etc. [20, 21] . Furthermore, transgenic mice encoding the FRET biosensors, called FRET mice, have been developed and used to visualize the activities of protein kinases and small GTPases in vivo [22, 23] .
For example, precise timing of ERK activation during extravasation has been visualized in neutrophils by the use of mice expressing a FRET biosensor for ERK [24] .
Here, we have attempted to visualize the spatiotemporal regulation of ERK and PKA activity to explore their roles during thrombus formation by using mice expressing FRET biosensors for ERK or PKA. Both ERK and PKA were activated in platelets during thrombus formation; however, the spatiotemporal characteristics of their activation differed significantly, showing how the propagation and resolution of the thrombus are controlled during the formation of a stable thrombus.
Materials and methods

Chemicals and antibodies
PD0325901 was purchased from EMD Millipore (Billerica, MA, USA). dbcAMP (Actosin) was purchased from Daiichi Sankyo (Tokyo, Japan). Qtracker 655 was purchased from Life Technologies (Carlsbad, CA, USA). Thrombin, forskolin, ADP, protease-activated receptor 4-activating peptide (PAR4-AP), phorbol 12-myristate 13-acetate (PMA) and collagen from bovine Achilles tendon were purchased from Sigma-Aldrich (Saint Louis, MO, USA). Isoflurane (Forane) was purchased from Wako (Osaka, Japan). PGI 2 was purchased from Cayman Chemical (Ann Arbor, MI, USA). 8-Bromo-cGMP and glyco-SNAP-1 were purchased from Calbiochem (San Diego, CA, USA). Phycoerythrin (PE)-conjugated antiactive glycoprotein (GP) IIb-IIIa (JON/A, no. M023-2), PE-conjugated anti-GPIba (Xia.G5, no. M040-2) and DyLight 649-conjugated anti-GPIIb-IIIa (Leo.F2, no. M025-3) were obtained from Emfret Analytics (W€ urzburg, Germany).
Mice
Transgenic mice expressing an ERK FRET biosensor (EKAREV-NES) (C57BL/6-TG[pT2A-3903NES]), a PKA FRET biosensor (AKAR3EV-NES) (C57BL/6-TG[pT2A-3901NES]) and a negative control FRET biosensor (PKA-NC) (C57BL/6-TG[pT2A-3906NES]) have been reported previously [22] . FRET mice were backcrossed for > 10 generations with C57BL/6 mice. Mice were housed in a specific-pathogen-free facility in temperature-controlled rooms with a 12-h light/12-h dark cycle, and received a routine chow diet and water ad libitum. To date, no disease or anomaly has been associated with the expression of the FRET biosensors used in this study. For the in vivo imaging, 8-24-week-old male or female mice were used. The animal protocols were reviewed and approved by the Animal Care and Use Committee of Kyoto University Graduate School of Medicine (No. 10584).
Preparation of washed platelet suspension and flow cytometry
Preparation of platelets and flow cytometry were performed essentially as described previously [25] . Blood was withdrawn from the control C57BL/6 and FRET mice, and collected directly into 0.38% (w/v) citric acid containing 5 lM PGI 2 . Platelet-rich plasma was obtained by centrifuging the blood sample twice at 100 9 g for 5 min. Platelets were sedimented by centrifugation of the platelet-rich plasma at 670 9 g for 5 min, and washed with Tyrode-HEPES buffer (137 mM NaCl, 2.7 mM KCl, 0.36 mM NaHPO 4 , 12 mM NaHCO 3 , 5 mM HEPES, and 5.5 mM glucose, pH 7.3) containing 0.35% bovine serum albumin. The washed platelets were resuspended in Tyrode-HEPES buffer (pH 7.3) and stimulated with ADP, PAR4-AP, or PMA, if necessary. The platelets were further incubated with 2.5 lL of antibodies for 15 min at room temperature, and analyzed on a FACScalibur (Becton Dickinson Japan, Tokyo, Japan).
In vitro FRET imaging of platelets Platelets were collected as described for the flow cytometry. The washed platelets were resuspended in Tyrode-HEPES buffer (pH 7.3) and seeded into collagen type I-coated 35-mm glass-based dishes (Asahi Techno Glass, Tokyo, Japan) at 3.75 9 10 7 platelets per dish. FRET imaging was performed essentially as described previously [26] . Platelets on the glass-baseed dish were observed with an IX83 inverted microscope (Olympus, Tokyo, Japan) equipped with a UPlanSApo 9 40/0.95 objective lens, a UPlanSApo 9 60/1.3 oil-immersion objective lens, a UPlanSApo 9 100/1.4 oil-immersion objective lens, a CCD camera (DOC-Cam HR-M; Molecular Devices, Sunnyvale, CA, USA), an EM-CCD camera (Rolera Thunder; QImaging, Surrey, British Columbia, Canada), an IX2-ZDC laser-based autofocusing system (Olympus), an automatic programmable XY stage (Sigma Koki, Hidaka, Japan), and an INUG2F-IX300 incubator system (Tokai-Hit, Fujinomiya, Japan). The following filters were used for the dual-emission imaging studies: a 430/24 filter and a 500/20 filter (Olympus) for the excitation of cyan fluorescent protein (CFP) and yellow fluorescent protein (YFP), respectively, and an XF2034 (455DRLP) dichroic mirror (Omega Optical, Brattleboro, VT, USA) and XF3075 (480AF30) (Omega Optical) and 535/30 (Olympus) filters for the detection of CFP and YFP, respectively. Platelets were imaged every 1 min for at least 40 min. Thrombin, forskolin, PGI 2 , 8-bromocGMP, ADP and glyco-SNAP1 were added at final concentrations of 0.5 U mL À1 , 10 nM, 100 nM, 3.0 mM, 10 lM, and 100 lM respectively. The acquired FRET images were processed and analyzed with METAMORPH (Universal Imaging, West Chester, PA, USA). The level of FRET was determined from the FRET/CFP ratio image in intensity-modulated display (IMD) mode; eight colors, from red to blue, were used to represent the FRET/CFP ratio, and the 32 grades of color intensity were used to represent the signal intensity of the CFP image. The warm and cold colors indicated high and low FRET levels, respectively.
Immunoblotting of platelets
Platelets were collected from the FRET mice as described for FRET imaging. Parallel-plate flow chamber assay
Platelet thrombus formation in flowing blood on immobilized collagen was analyzed with a parallel-plate flow chamber as described previously [27] . Acid-insoluble type I collagen-coated glass coverslips were placed in a flow chamber. The chamber was mounted on the aforementioned fluorescence microscope. Blood was collected into tubes containing 3.8% sodium citrate. Whole blood samples were aspirated through the chamber and across the collagen-coated coverslip at 0. 
In vivo FRET imaging by two-photon excitation microscopy
In vivo FRET imaging was performed essentially as described previously, with an FV1000MPE inverted microscope (Olympus) equipped with a 9 30/1.05 NA silicon oil-immersion objective lens (UPlanSApo X30/1.05 NA; Olympus), an Insight DeepSee Ultrafast laser (0.95 W at 900 nm; Spectra Physics, Mountain View, CA, USA), and two GaAsP detector units and two built-in photomultiplier tubes [24] . The laser power used for observation was 4-10%. Mice were anesthetized by 1-1.5% isoflurane inhalation, and placed in the face-down position on an electric heat pad maintained at 37°C. A linear incision was made in the abdominal skin. The subcutaneous connective tissue was separated to free the skin flap, which was placed on a coverglass at the center of a heat-stage maintained at 37°C. Subcutaneous arterioles with a diameter of 10-30 lm were subjected to observation. Direct laser-induced injuries were made in the subcutaneous arterioles by momentarily exposing a small area of the vessel wall to a laser of 600-1100-mW power at 840 nm. Injuries were made on the luminal surface at the side of the vessel wall. In some experiments, 25 mg kg À1 PD0325901 MEK inhibitor in phosphatebuffered saline or 0.5 g kg À1 dbcAMP was administered via the orbital plexus at the start or during the course of in vivo imaging. To visualize the arterioles, 4 lL of Qtracker 655 was coinjected with the drugs. Mice were killed after the experiments.
Image processing
Acquired images were analyzed with METAMORPH as described previously [22, 26] . Briefly, the level of FRET was shown by the FRET/CFP ratio image in IMD mode; eight colors from red to blue were used to represent the FRET/CFP ratio, and the 32 grades of color intensity were used to represent the signal intensity of the CFP image. The warm and cold colors indicated high and low FRET levels, respectively. For better presentation of thrombus, a 5 9 5 median filter was applied to the FRET/CFP ratio images.
Statistical analysis
P-values for normally distributed data were calculated with Student's t-test, Student's paired t-test, the Bartlett test or one-factor repeated measures ANOVA for the evaluation of statistically significant differences. Data analysis was performed with Excel software or GRAPHPAD PRISM (GraphPad Software, La Jolla, CA, USA).
Results
Live imaging of PKA and ERK activity in ligand-stimulated platelets
The FRET biosensors for PKA and ERK comprised a phospho-peptide-binding domain and a substrate peptide, which were sandwiched by CFP and YFP. The phosphorylation level of the FRET biosensors correlated with the FRET signal, which was normalized to the level of the amount of the biosensor by use of the FRET/CFP value (Fig. 1A) . Transgenic mice expressing the FRET biosensors have been used previously to visualize activity changes of PKA and ERK in neutrophils and epidermal cells [24, 28] . We did not find significant differences in the expression levels of GPIba and GPIIb-IIIa between the transgenic mice and the wild-type C57BL/6 mice, except that transgenic mice expressing a negative-control FRET biosensor showed slightly decreased expression of both antigens (Fig. S1A,B) . We did not find any significant difference in the agonist-stimulated expression of active GPIIb-IIIa between the transgenic mice and the wild-type C57BL/6 mice. We then confirmed the response of FRET biosensors in platelets by using known activators of ERK and PKA. Here, the activities of ERK and PKA were represented by the FRET/CFP ratio images, which are shown in IMD mode with 32 grades of color intensity in 8-ratio as indicated by the color bars. The warm and cold colors indicate higher and lower activities, respectively. Platelets derived from mice expressing a FRET biosensor for ERK showed a rapid increase in the FRET/CFP ratio upon thrombin stimulation (Fig. 1B,C) . The increase in FRET/CFP was reversed by addition of the MEK inhibitor PD0325901. Immunoblotting with anti-ERK and antiphospho-ERK showed a similar pattern of activation (Fig. 1C) . dbcAMP did not induce ERK activation to a detectable level. Platelets derived from mice expressing a FRET biosensor for PKA showed rapid increase in the FRET/CFP ratio upon stimulation with forskolin and PGI 2 , both of which are known to activate PKA (Fig. 1D ). 8-BromocGMP and thrombin caused a modest increase in the FRET/CFP ratio. ADP and Glyco-SNAP-1 did not increase the FRET/CFP ratio to a detectable extent.
We further explored the response of the FRET biosensor during thrombus formation under fluid shear stress (Fig. 1E) . As expected from the positive and negative roles of ERK and PKA, respectively, only platelets derived from the mice expressing a FRET biosensor for ERK showed a rapid increase in the FRET/CFP ratio during adhesion to the collaged-coated coverglasses. Furthermore, we also found weak, but clear, PKA activation. These observations were also in support of FRET biosensors being valuable tools for the measurement of ERK or PKA phosphorylation in platelets.
ERK activation during thrombus formation in vivo
We chose subcutaneous arterioles with a diameter of 10-30 lm for observation by two-photon excitation microscopy, because of easy setup. Similarly to the method reported previously [29] , a deep injury was induced at the arterial wall by momentarily increasing the laser power. Platelet aggregation and thrombus formation after laser ablation followed essentially the same process as observed in previous in vivo imaging studies with mesenteric or cremaster arterioles ( Fig. 2 ; Video S1) [11, [29] [30] [31] [32] [33] . The laser-induced tissue damage generated autofluorescent substances, which clearly marked the laser-ablated site. In the transgenic mice used in this study, the FRET biosensors were expressed in the cytoplasm of leukocytes and platelets, but not in red blood cells (Fig. 1B) . Therefore, leukocytes could be unambiguously discriminated from platelets by their sizes and nucleus-sparing pattern. In the initiation phase, which began immediately after laser ablation, discoid platelets initially attached loosely to the damaged vessel wall. As is observed during shear-induced thrombus formation [34] , cycles of aggregation and disaggregation of platelets began in the propagation phase. After the initial growth phase, the aggregated platelets were eventually packed to form an adhesive thrombus on the damaged arteriole, as described previously [11] . In the stabilization phase, the aggregates formed a thrombus, the size of which no longer changed, although, occasionally, a small number of platelets were loosely attached to the thrombus. In the initiation phase, ERK activity in the recruited platelets remained low. In the late propagation phase, when ERK activity was increased in the platelets near the damaged vessel wall, the platelet aggregate started to contract to form a stable thrombus. The ERK activity in the thrombus remained high thereafter. During the stabilization phase, platelets in the blood flow attached to and detached from the surface of the mural thrombus repeatedly, although ERK activity was not increased in such transiently associating platelets ( Fig. 2A,B ; Video S1).
Although the morphology and time course varied, similar observations were constantly observed in the laserablated blood vessels.
PKA activation during thrombus formation
We used the same protocol for the visualization of PKA activity ( Fig. 3A,B ; Video S2). The pattern of PKA activation was clearly different from that of ERK; a change in the activity of PKA was not observed in the initiation phase. In the propagation phase, PKA activity started to increase in platelets detaching from the downstream side of the aggregate, suggesting that high PKA activity is associated with thrombus resolution. In the stabilization phase, a large proportion of the thrombus showed high PKA activity. We confirmed the specificity of FRET signal changes by using another transgenic mouse line expressing a negative control FRET biosensor, PKA-NC, in which the phosphorylation site of the PKA FRET biosensor was mutated (Fig. 3C,D) . No significant changes in the FRET level were observed with this negative control mouse.
An essential role of ERK in platelet aggregation and thrombus formation
To understand the role of ERK during thrombus formation, MEK, the activator of ERK, was inhibited by PD0325901. When PD0325901 was injected before laser ablation, the recruitment of platelets to the injured blood wall was markedly impaired. This observation indicates that basal ERK activity is indispensable in the initiation of platelet aggregation, even though we failed to detect ERK activation during the first few minutes of platelet aggregation (Fig. 4A) . Next, we examined the effect of the MEK inhibitor after thrombus formation ( Fig. 4B-E ; Video S3). The ERK activity gradually decreased, and this was followed by the dislodgement of thrombus from the injured site, indicating that the high ERK activity in the contracted thrombus is still required for adhesion, at least within the observed time frames.
PKA inhibition of platelet aggregation
The role played by PKA was examined by use of a cAMP analog, dbcAMP. When dbcAMP was intravenously administered before laser ablation, platelet aggregation was markedly impaired (Fig. 5A) , which is consistent with the reported role of PKA as a negative regulator of platelet activation. Next, we injected dbcAMP in the stabilization phase, when the aggregation-disaggregation cycle continues ( Fig. 5B-D ; Video S4). The aggregation of platelets on the preformed thrombus was inhibited by dbcAMP ( Fig. 5B-C) . However, in contrast to the MEK inhibitor, dbcAMP did not induce dislodgement of the preformed thrombus (Fig. 5D ). Because PKA activity remained high in the thrombus, the results showed that PKA activation is not sufficient for dislodgement of the thrombus from the injured vessels. In neutrophils, PKA activation suppresses ERK activity [24] . Therefore, we examined the effect of dbcAMPinduced PKA activation on ERK activity. In contrast to our expectation, we did not find any changes in ERK activity in the thrombus, indicating that PKA cannot inhibit ERK in the thrombus (Fig. 5E,F) . This lack of ERK inhibition is in agreement with the observed ineffectiveness of dbcAMP to the abolishment of preformed thrombus.
Discussion
PKA is known as a major signal transducer of PGI 2 [17, 18] . Nevertheless, the changes in PKA activity during thrombus formation remain elusive, because of technical difficulties. We originally expected that PKA activity would be decreased during platelet activation, because ADP, a potent activator of platelets, transduces signals through the G i2 -coupled P2Y 12 receptor [35] , and that G i2 deficiency induces to increase the basal cAMP level within platelets [36] . In contrast to our expectation, we failed to observe a decrease in PKA activity in the core of the thrombus, but noticed that PKA was activated at the downstream side of the shell (Figs 3 and 5) . This observation may suggest that the primary role of ADP and the following G i2 activation is to counteract the effects of other G s -stimulating molecules in the shell of the growing thrombus. In agreement with this, the expression of constitutively active G i2a increases the size of the shell without affecting the size of the core of the thrombus [11] . In the present study, we distinguished the core and the shell of the thrombus primarily according to the morphology and the time course of adherence. Simultaneous staining of the core region with anti-P-selectin antibody [11] , which was used successfully in the previous study, will show a more precise correlation between the activation of platelets and activity changes of PKA and ERK.
Previous in vitro studies have suggested that, in the platelets recruited to the damaged blood vessels, ERK is immediately activated either by G-protein-coupled receptors for thrombin, ADP, and TxA 2 , or by GPIb bound to VWF [12, 37] . Under physiologic shear stress conditions, however, the platelet aggregation is divided into a first phase without platelet activation, and a second phase associated with platelet shape change to form a core of activated platelets [10, 11] . We found that ERK activity remained low in the platelets forming loose aggregates, but increased robustly during the contraction of aggregated platelets to form the core of the thrombus (Fig. 2) . Counterintuitively, the MEK inhibitor suppressed the tethering and aggregation of platelets, suggesting that ERK activity is indispensable for not only the second phase but also the first phase of platelet aggregation (Fig. 4) . There are at least two possible explanations for this discrepancy. First, even though the level of ERK activation is lower than the detectable level, this low level of ERK activation in the platelet may still be required for the initial loose aggregation. Assuming that a 10% FRET change is detectable, we are able to monitor a 3% ERK activity change [38] . It appears unlikely that a < 3% ERK activity increase in discoid platelets contributed to the aggregation of the platelets. Second, the basal ERK activity of platelets in the blood flow may be indispensable for the aggregation of discoid platelets. Aggregation of the platelets under high shear conditions is primarily driven by changes in blood rheology [2] , and is dependent primarily on adhesion molecules such as GPIba and GPIIb-IIIa mediating association with collagen fibers and other platelets [39] . Furthermore, locally generated soluble agonists such as thromboxane A 1 and ADP, and cell adhesion molecules, including the CTX family and PECAM-1, also modulate aggregate formation. The basal ERK activity may play a role in displaying a small number of active adhesion molecules on the surfaces of platelets, which is indispensable for the tethering of platelets.
We have shown that two-photon excitation microscopy with FRET mice may pave the way to visualizing the activities of signaling molecules such as ERK and PKA during thrombus formation. However, some limitations have also become evident. First, in some experiments, we could examine only three to four mice for each condition [24] , because the supply of mice was still limited. The installation of imaging windows or a needle lens enables observation of the same mouse repeatedly, and will save animals [40] . Second, the spatiotemporal resolution was not sufficient to capture the activation of a single platelet. Third, we cannot conclude whether the inhibitors and stimulators affected platelets directly or indirectly by means of chemical mediators derived from endothelial cells (Figs 4 and 5) . Last, but not least, the specificity of the FRET biosensors should be considered when the results are interpreted. The consensus substrate peptide used in the FRET biosensor for the protein kinase of interest could be phosphorylated by other protein kinases. Thus, in vitro biochemical experiments or validation by the use of inhibitors must follow the in vivo FRET imaging to further explore the mechanism underlying the phenomena. S1 . Platelets isolated from control C57BL/6 and transgenic mice expressing the FRET biosensors were analyzed for the expression of GPIb (A) and GPIIb-IIIa (B). (C) Platelets were stimulated with ADP, PAR4-AP, or PMA and analyzed by flow cytometry for the expression of activated GPIIb-IIIa. Video S1. In vivo visualization of ERK activation at the bottom of the thrombus. Video S2. In vivo visualization of PKA activation in the downstream side of the torombus. Video S3. Requirement of ERK activity for thrombus formation. Video S4. dbcAMP activation of PKA in platelets.
